Mostra el registre d'ítem simple

dc.contributor.authorGago López, Nuria
dc.contributor.authorLagunas Arnal, Carmen
dc.contributor.authorPérez González, Juan Jesús
dc.contributor.authorWagner, Erwin F.
dc.contributor.otherUniversitat Politècnica de Catalunya. Departament d'Enginyeria Química
dc.date.accessioned2021-11-04T11:39:00Z
dc.date.available2021-11-04T11:39:00Z
dc.date.issued2021-11-30
dc.identifier.citationGago, N. [et al.]. Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model. "Experimental Dermatology", 30 Novembre 2021, vol. 30, núm. 11, p. 1662-1674.
dc.identifier.issn1600-0625
dc.identifier.urihttp://hdl.handle.net/2117/355589
dc.description.abstractPsoriasis is a chronic inflammatory skin disease without cure. Systemic and biological therapies are the most effective treatments for patients with severe psoriasis. However, these drugs can cause serious side effects from extended use. Safe and effective topical drugs are needed to decrease psoriatic plaques and reduce the risk of adverse effects. Amygdalin analogues are stable small molecules that showed benefits in psoriasis xenografts to immune-deficient mice by systemic application. However, whether topical application of these amygdalin analogues could reduce the progression of the psoriatic phenotype in an immune-competent organism is unknown. Here, we analyse the efficiency of topical application of an amygdalin analogue cream on a well-established genetic and immune-competent mouse model of psoriasis. Topical application of an amygdalin analogue cream ameliorates psoriasis-like disease in mice, reduces epidermal hyperplasia and skin inflammation. Amygdalin analogue treatment leads to reduced expression of local pro-inflammatory cytokines, but systemic pro-inflammatory cytokines that are highly expressed in psoriasis patients such as IL-17A, IL6 or G-CSF are also decreased. Furthermore, expression of important mediators of psoriasis initiation and epidermal hyperplasia, such as TNFa, S100A9 and TSLP, is decreased in lesional epidermis after amygdalin analogue treatment. In conclusion, we show that amygdalin analogue reduces the proliferative capacity of psoriasis-like stimulated keratinocytes and their inflammatory response in vivo and in vitro. These results suggest that topical application of amygdalin analogues may represent a safe and effective treatment for psoriasis.
dc.format.extent13 p.
dc.language.isoeng
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Spain
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subjectÀrees temàtiques de la UPC::Enginyeria química
dc.titleTopical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model
dc.typeArticle
dc.subject.lemacDermatologia
dc.subject.lemacPsoriasi -- Tractament
dc.contributor.groupUniversitat Politècnica de Catalunya. GBMI - Grup de Biotecnologia Molecular i Industrial
dc.identifier.doi10.1111/exd.14390
dc.description.peerreviewedPeer Reviewed
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/exd.14390
dc.rights.accessOpen Access
local.identifier.drac32010330
dc.description.versionPostprint (published version)
local.citation.authorGago, N.; Lagunas, C.; Perez, J.; Wagner, E.
local.citation.publicationNameExperimental Dermatology
local.citation.volume30
local.citation.number11
local.citation.startingPage1662
local.citation.endingPage1674


Fitxers d'aquest items

Thumbnail

Aquest ítem apareix a les col·leccions següents

Mostra el registre d'ítem simple